Lenvatinib is a multi-targeted tyrosine kinase inhibitor, and in this entry it is described as part of a proposed conversion therapy regimen for hepatocellular carcinoma. It has also been used as a comparator/prior treatment option in unresectable hepatocellular carcinoma, reflecting its role in advanced liver cancer management. Beyond liver cancer, it was investigated for potentiating antitumor efficacy in lung adenocarcinoma when combined with radiotherapy and PD-L1 blockade. Overall, the literature here highlights lenvatinib as an antitumor agent studied in combination strategies rather than as a single-agent therapy. The cited studies include a 2026 protocol for cadonilimab plus lenvatinib with stereotactic body radiotherapy and a 2026 Cancer Biology & Therapy study on radiotherapy plus PD-L1 blockade.
Hepatocellular carcinoma
- Lenvatinib was included in a proposed conversion therapy regimen with cadonilimab and stereotactic body radiotherapy for unresectable or potentially resectable hepatocellular carcinoma (PMID:41954707).
- The study protocol frames lenvatinib as part of a combination approach aimed at conversion therapy rather than standalone treatment (PMID:41954707).
- It was also described as a comparator drug previously used in unresectable hepatocellular carcinoma (PMID:41981891).
- The 2026 Current Medical Science protocol specifically evaluates cadonilimab plus lenvatinib with stereotactic body radiotherapy in this disease setting (PMID:41954707).
Lung adenocarcinoma
- Lenvatinib was investigated for its ability to potentiate antitumor efficacy when combined with radiotherapy and PD-L1 blockade in lung adenocarcinoma (PMID:41481002).
- The study suggests a radiosensitizing or immunotherapy-enhancing role for this multi-targeted tyrosine kinase inhibitor (PMID:41481002).
- This work extends lenvatinib’s relevance beyond liver cancer into thoracic oncology combination therapy research (PMID:41481002).